Please login to the form below

Not currently logged in

Stem cell

This page shows the latest Stem cell news and features for those working in and with pharma, biotech and healthcare.

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

Cell therapy disruptor Mogrify gains $3.7m in funding and a new leader

mature cell type – without needing to transition through a stem cell. ... The platform can also be applied to other treatment areas, including cardiac repair and cartilage regeneration, areas that previously demonstrated limited efficacy with currently

Latest news

More from news
Approximately 7 fully matching, plus 193 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The analysts predict the drug will be priced at around $550,

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Raju Prasad says Bluebird can offer a compelling cost-effectiveness case for its treatment in beta thalassemia and sickle cell cases versus conventional stem cell treatment. ... Conventional stem cell transplants cost anywhere between $500, 000 and $1m,

  • Reaching the new influencers Reaching the new influencers

    Right now, we’re living through healthcare’s age of accelerations - as evidenced by advances in everything from biotechnology and stem cell research to machine learning and the advent (and approvals)

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... way under the cost-effective price and significantly lower than the current standard of allogenic stem cell transplant that costs $500, 000-800, 000 in the first year with follow-up

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel),

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory ... be a global leader in the

  • Porterhouse Medical promotes Emma Conran Porterhouse Medical promotes Emma Conran

    Conran has served in medical writing positions at Porterhouse Medical since 2014 and prior to that she was a translational stem cell biology lecturer at King’s College London.

  • apceth Biopharma appoints Dusan Kosijer as CFO apceth Biopharma appoints Dusan Kosijer as CFO

    successful track record as one of the leading CDMOs for complex cell and gene therapy products. ... Moreover, Dusan’s experience will strongly promote our dynamic innovative strategy behind apceth’s unique proprietary pipeline of genetically modified

  • Dr Jay Stout moves from Merck to SanBio Dr Jay Stout moves from Merck to SanBio

    In this role, he is responsible for all production-related operations, including clinical cell preparation, final quality assurance and process development. ... He is perhaps the individual with the greatest experience in the world in manufacturing

More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Pegasus expands Pharma team with senior hires

    He has delivered brand and advertising campaigns for a range of clients including Roche, UK Stem Cell Foundation and Department of Health, as well as BBC Worldwide, Procter &Gamble and Amazon.

  • Highlights in haematologic malignancy from ASH 2018

    A reduced risk of relapse was also seen when CD19-directed CAR T-cell therapy was followed by a first-time stem cell transplant in children with ALL. ... stem cell transplant for higher risk patients and less aggressive treatments for others).

  • Solaris Health looks at the gene therapy revolution

    As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene therapy approved by the EMA (European Medicines ... 1. The ground-breaking treatment uses a virus to

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... Dr Ivan Wall is an expert in all things stem cell.

  • Biotech: it's a people business

    From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of

More from PMHub
Approximately 2 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...